Tom Lavin is a co-founder and Partner of New Science Ventures. He serves on the Board of Directors for Achronix Semiconductor Corporation and Light Sciences Oncology and is an observer on the boards of Vorago, Juventas Therapeutics and Therox. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was a senior professional in finance and investment banking for over 30 years. Tom has extensive experience in private and public equity and debt transactions, mergers and acquisitions and financial restructurings in the U.S. and abroad. He was head of real estate investment banking at First Boston and Smith Barney and head of commercial mortgage lending at MetLife. Tom holds an A.B. degree in Government from Wesleyan University and an M.B.A. from Harvard Business School.